Targeting the Sumoylation Pathway in Synovial Sarcoma
Abstract
Synovial sarcoma (SS) is a rare cancer and commonly affects adolescents and young adults in the age range of 15-40. Although the principal genetic lesion in this disease is well established, targeted therapies do not exist. Current treatment options include surgery, chemotherapy, and radiotherapy. There is a clear need for novel targeted therapeutic strategies for SS. In this project, we propose to test the idea that SS could be particularly vulnerable to drugs that target sumoylation, a part of the cellular protein quality control mechanism. Thus, this proposal addresses the Fiscal Year 2021 Rare Cancers Research Program Focus Area Therapy: Identify novel therapeutic strategies, including drug repurposing. If successful, our proposed studies could establish the importance of the sumoylation in SS. Furthermore, this could set the stage for evaluating this class of drugs as therapeutic agents in SS and prompt immediate follow-up mechanistic studies preclinical work in animal models and lay the groundwork for future clinical studies in human patients.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2210938
Entities
People
- Senthil Radhakrishnan
Organizations
- United States Army
- Virginia Commonwealth University